Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruce Barton

Neurology Jupiter, FL Medical Doctor

NPI 1104005925 CMS profile 1291668

601 University Blvd Ste 102, Jupiter, FL 33458

Open in the dashboard

General payments

$7,033

416 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bruce Barton of Jupiter, FL is reported in the CMS Open Payments database as having received $7,033 across 416 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24 1
2023 General $1,387 60
2022 General $1,991 111
2021 General $2,121 129
2020 General $896 65
2019 General $614 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Barton
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Bruce Barton were reported at $24. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Bruce Barton Neurology median Middle half National median
2019 $614 $474 $118–$2,177 $163
2020 $896 $367 $82–$2,309 $114
2021 $2,121 $438 $104–$2,547 $132
2022 $1,991 $442 $103–$2,388 $149
2023 $1,387 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $24 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,159 60 payments
  2. Amgen Inc. $858 65 payments
  3. Novartis Pharmaceuticals Corporation $834 51 payments
  4. Biohaven Pharmaceuticals, Inc. $600 39 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $518 33 payments
  6. Teva Pharmaceuticals USA, Inc. $448 22 payments
  7. Genzyme Corporation $411 17 payments
  8. Allergan Inc. $214 21 payments
  9. Upsher-Smith Laboratories LLC $190 11 payments
  10. Pfizer Inc. $181 9 payments
  11. Other $1,620 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,950 410 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $70 5 payments
  3. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. AIMOVIG $1,372 101 payments
  2. NURTEC ODT Primary Care $1,119 72 payments
  3. UBRELVY Neuroscience $860 45 payments
  4. AJOVY $403 19 payments
  5. AUBAGIO $374 15 payments
  6. QULIPTA $272 9 payments
  7. NURTEC ODT Pain $181 9 payments
  8. UBRELVY Neuroscience $174 17 payments
  9. TOSYMRA $150 8 payments
  10. ZEMBRACE SYMTOUCH $150 8 payments
  11. Other $2,639 144 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

578

Median for Psychiatry & Neurology: 100

Drug cost

$19,872

Median for Psychiatry & Neurology: $2,986

Branded share of claims

21.5%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aimovig Autoinjector Erenumab-Aooe Brand 14 $10,241
Butalbital-Acetaminophen-Caffe Butalb/Acetaminophen/Caffeine Brand 64 $1,615
Propranolol Hcl Er Propranolol Hcl Brand 17 $879
Gabapentin Generic 39 $846
Amitriptyline Hcl Generic 31 $773
Duloxetine Hcl Generic 28 $539
Rizatriptan Rizatriptan Benzoate Brand 17 $482
Phenytoin Sodium Extended Generic 14 $470
Tramadol Hcl Generic 35 $425
Pregabalin Generic 21 $400

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Records

416 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record